Nombre del producto:2,4-difluorobenzene-1-thiol

IUPAC Name:2,4-difluorobenzene-1-thiol

CAS:1996-44-7
Fórmula molecular:C6H4F2S
Pureza:95%+
Número de catálogo:CM379550
Peso molecular:146.15

Unidad de embalaje Stock disponible Precio($) Cantidad
CM379550-10g in stock ȐǑ
CM379550-25g in stock ȯƿǑ
CM379550-100g in stock ƛƿȯ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1996-44-7
Fórmula molecular:C6H4F2S
Punto de fusión:-
Código de sonrisas:FC1=CC(F)=C(S)C=C1
Densidad:
Número de catálogo:CM379550
Peso molecular:146.15
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Neflamapimod
Dementia with Lewy Bodies (DLB) is a rapidly progressive neurodegenerative disorder with a significant aging population and unmet health need. Alterations in p38 mitogen-activated protein kinases (MAPKs) are found to contribute to the neurodegenerative process in Alzheimer's disease (AD) and related dementias.
CervoMed’s Neflamapimod (VX-745) is an oral, brain penetrant, small molecule inhibitor of the protein kinase p38α. It is designed to specifically target the mechanisms that cause dysfunction and degeneration of neurons in the basal forebrain cholinergic system. Neflamapimod has the potential of reversing synaptic dysfunction in the basal forebrain. The positive phase 2a data was published in Nature Communications, Neurology, and JPAD. Neflamapimod was granted Fast Track Designation by the FDA for DLB, and phase 2b enrollment was completed in June, 2024.